ZA201206725B - Stabilized alpha-galactosidase and uses thereof - Google Patents

Stabilized alpha-galactosidase and uses thereof

Info

Publication number
ZA201206725B
ZA201206725B ZA2012/06725A ZA201206725A ZA201206725B ZA 201206725 B ZA201206725 B ZA 201206725B ZA 2012/06725 A ZA2012/06725 A ZA 2012/06725A ZA 201206725 A ZA201206725 A ZA 201206725A ZA 201206725 B ZA201206725 B ZA 201206725B
Authority
ZA
South Africa
Prior art keywords
galactosidase
stabilized alpha
stabilized
alpha
Prior art date
Application number
ZA2012/06725A
Other languages
English (en)
Inventor
Avidor Shulman
Llya Ruderfer
Tehila Ben-Moshe
Talia Shekhter
Yaniv Azulay
Yoseph Shaaltiel
Tali Kizhner
Original Assignee
Protalix Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IL2010/000956 external-priority patent/WO2011061736A1/en
Application filed by Protalix Ltd filed Critical Protalix Ltd
Publication of ZA201206725B publication Critical patent/ZA201206725B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y302/00Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01022Alpha-galactosidase (3.2.1.22)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/24Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2465Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/47Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/525Tumour necrosis factor [TNF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
ZA2012/06725A 2010-03-02 2012-09-07 Stabilized alpha-galactosidase and uses thereof ZA201206725B (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US30948710P 2010-03-02 2010-03-02
PCT/IL2010/000956 WO2011061736A1 (en) 2009-11-17 2010-11-17 Alkaline alpha galactosidase for the treatment of fabry disease
US201161434503P 2011-01-20 2011-01-20
US201161434499P 2011-01-20 2011-01-20
PCT/IL2011/000209 WO2011107990A1 (en) 2010-03-02 2011-03-02 Stabilized alpha-galactosidase and uses thereof

Publications (1)

Publication Number Publication Date
ZA201206725B true ZA201206725B (en) 2013-06-26

Family

ID=44121635

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2012/06725A ZA201206725B (en) 2010-03-02 2012-09-07 Stabilized alpha-galactosidase and uses thereof

Country Status (23)

Country Link
EP (3) EP2865751B1 (cg-RX-API-DMAC7.html)
JP (2) JP5758920B2 (cg-RX-API-DMAC7.html)
KR (1) KR101928403B1 (cg-RX-API-DMAC7.html)
CN (1) CN102933707B (cg-RX-API-DMAC7.html)
AU (1) AU2011222452B2 (cg-RX-API-DMAC7.html)
BR (2) BR122014021216A2 (cg-RX-API-DMAC7.html)
CA (1) CA2791461C (cg-RX-API-DMAC7.html)
DK (1) DK2865751T3 (cg-RX-API-DMAC7.html)
ES (2) ES2708843T3 (cg-RX-API-DMAC7.html)
FI (1) FIC20230032I1 (cg-RX-API-DMAC7.html)
FR (1) FR23C1041I2 (cg-RX-API-DMAC7.html)
HR (1) HRP20200428T1 (cg-RX-API-DMAC7.html)
HU (2) HUE030959T2 (cg-RX-API-DMAC7.html)
IL (2) IL221741A (cg-RX-API-DMAC7.html)
IN (1) IN2012MN02262A (cg-RX-API-DMAC7.html)
NL (1) NL301249I2 (cg-RX-API-DMAC7.html)
NO (1) NO2023041I1 (cg-RX-API-DMAC7.html)
NZ (2) NZ623294A (cg-RX-API-DMAC7.html)
PL (1) PL2865751T3 (cg-RX-API-DMAC7.html)
SG (2) SG183558A1 (cg-RX-API-DMAC7.html)
SI (1) SI2865751T1 (cg-RX-API-DMAC7.html)
WO (1) WO2011107990A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201206725B (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9194011B2 (en) 2009-11-17 2015-11-24 Protalix Ltd. Stabilized alpha-galactosidase and uses thereof
CN102933707B (zh) * 2010-03-02 2015-09-30 普罗塔里克斯有限公司 稳定的α-半乳糖苷酶及其用途
RS60129B1 (sr) * 2011-01-20 2020-05-29 Protalix Ltd Kompozicije alfa-galaktozidaze
TW202332774A (zh) * 2013-10-23 2023-08-16 美商健臻公司 重組醣蛋白及其用途
EP3237621B1 (en) * 2014-12-22 2023-04-19 Codexis, Inc. Human alpha-galactosidase variants
WO2016116966A1 (en) * 2015-01-22 2016-07-28 Jcr Pharmaceuticals Co., Ltd. Method for purification of recombinant human alpha-galactosidase a from material containing contaminant host cell proteins
JP6936150B2 (ja) 2015-03-17 2021-09-15 エレヴァ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングeleva GmbH グリコシル化リソソームタンパク質、その製造方法および使用
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
WO2018127920A1 (en) 2017-01-05 2018-07-12 Protalix Ltd. Therapeutic regimen for the treatment of fabry using stabilized alpha-galactosidase
US11517613B2 (en) * 2017-06-07 2022-12-06 Amano Enzyme Inc. Lactase bulk powder and lactase preparation
KR102898199B1 (ko) 2018-12-20 2025-12-09 코덱시스, 인코포레이티드 인간 알파 갈락토시다제 변이체
CN116096898A (zh) * 2020-02-28 2023-05-09 科德克希思公司 人类α半乳糖苷酶变体
EP4240423A1 (en) 2020-11-03 2023-09-13 Protalix Ltd. Modified uricase and uses thereof
CN112176026A (zh) * 2020-11-06 2021-01-05 诺道中科(北京)生物科技有限公司 一种α-半乳糖苷酶活性的检测试剂盒
CN116254287B (zh) * 2022-11-24 2024-06-04 西北农林科技大学 玉米ZmAGA3基因用于提高植物耐旱性的应用
CN118243646B (zh) * 2024-04-24 2025-01-24 武汉简为医疗科技有限公司 一种乳糖不耐受检测试剂盒及其使用方法
JP7745040B1 (ja) * 2024-06-21 2025-09-26 デンカ株式会社 目的タンパク質の回収方法及び製造方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766897A (en) 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
US5401650A (en) * 1990-10-24 1995-03-28 The Mount Sinai School Of Medicine Of The City University Of New York Cloning and expression of biologically active α-galactosidase A
CA2052728A1 (en) 1991-10-03 1993-04-04 Guy Ampleman Glycidyl azide polymer
US6329191B1 (en) * 1993-08-30 2001-12-11 Hawaii Biotechnology Group, Inc. DNA encoding recombinant coffee bean alpha-galactosidase
US6458574B1 (en) * 1996-09-12 2002-10-01 Transkaryotic Therapies, Inc. Treatment of a α-galactosidase a deficiency
US20050032211A1 (en) * 1996-09-26 2005-02-10 Metabogal Ltd. Cell/tissue culturing device, system and method
WO1999012959A1 (en) * 1997-09-05 1999-03-18 Altus Biologics Inc. Carbohydrate crosslinked glycoprotein crystals
IL125423A (en) 1998-07-20 2004-08-31 Israel State Alkaline alpha-galactosidase having broad substrate specificity
CA2369869C (en) * 1999-04-02 2008-06-10 Ajinomoto Co., Inc. Process for producing subunit peptide originating in polymer protein
EP1523548B1 (en) 2002-05-15 2009-12-30 Agricultural Research Organization Polynucleotide sequences encoding alkaline a-galactosidases and methods of using same
US7951557B2 (en) * 2003-04-27 2011-05-31 Protalix Ltd. Human lysosomal proteins from plant cell culture
JP5137814B2 (ja) * 2005-04-06 2013-02-06 ジェンザイム・コーポレーション 治療ターゲティングのための酸不安定リンカーを介するpegおよびポリシアルリソソーム酵素のコンジュゲート
JP4368925B2 (ja) * 2005-11-18 2009-11-18 財団法人 東京都医学研究機構 基質特異性を変換した新規高機能酵素
EP2121005A1 (en) 2006-12-21 2009-11-25 Academisch Ziekenhuis bij de Universiteit van Amsterdam Treatment of fabry disease
JP2008169195A (ja) * 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd キャリア物質を用いたインスリン分泌ペプチド薬物結合体
EP1955712A1 (en) * 2007-02-09 2008-08-13 Scil proteins GmbH Multimeric conjugate
CA2696699A1 (en) 2007-08-20 2009-02-26 Protalix Ltd. Saccharide-containing protein conjugates and uses thereof
CN102933707B (zh) * 2010-03-02 2015-09-30 普罗塔里克斯有限公司 稳定的α-半乳糖苷酶及其用途

Also Published As

Publication number Publication date
HUE030959T2 (en) 2017-06-28
FIC20230032I1 (fi) 2023-11-02
CN102933707B (zh) 2015-09-30
FR23C1041I1 (cg-RX-API-DMAC7.html) 2023-12-29
CA2791461C (en) 2019-10-22
PL2865751T3 (pl) 2017-03-31
EP3088514B1 (en) 2018-11-28
EP2542675A1 (en) 2013-01-09
JP5758920B2 (ja) 2015-08-05
ES2606532T3 (es) 2017-03-24
KR20130056216A (ko) 2013-05-29
EP2542675B1 (en) 2014-12-17
JP5871999B2 (ja) 2016-03-01
BR112012022029A2 (pt) 2021-05-18
JP2014237694A (ja) 2014-12-18
NL301249I1 (cg-RX-API-DMAC7.html) 2023-11-08
HK1180720A1 (en) 2013-10-25
CA2791461A1 (en) 2011-09-09
BR122014021216A2 (pt) 2021-06-01
EP2865751A1 (en) 2015-04-29
SG183558A1 (en) 2012-10-30
SG10201502609QA (en) 2015-05-28
IL253249B (en) 2020-08-31
NZ602317A (en) 2014-04-30
BR112012022029B1 (pt) 2022-10-11
CN102933707A (zh) 2013-02-13
KR101928403B1 (ko) 2018-12-14
IL253249A (en) 2019-08-29
NZ623294A (en) 2015-10-30
FR23C1041I2 (fr) 2024-08-02
EP2865751B1 (en) 2016-09-14
HRP20200428T1 (hr) 2020-06-12
NO2023041I1 (no) 2023-11-01
NL301249I2 (nl) 2023-12-14
IL221741A (en) 2017-07-31
JP2013520986A (ja) 2013-06-10
AU2011222452B2 (en) 2015-09-03
DK2865751T3 (en) 2017-01-09
ES2708843T3 (es) 2019-04-11
EP3088514A1 (en) 2016-11-02
HUS2300038I1 (hu) 2023-11-28
IN2012MN02262A (cg-RX-API-DMAC7.html) 2015-06-12
AU2011222452A1 (en) 2012-09-27
WO2011107990A1 (en) 2011-09-09
RU2604795C2 (ru) 2016-12-10
RU2012141651A (ru) 2014-04-10
SI2865751T1 (sl) 2017-01-31

Similar Documents

Publication Publication Date Title
HUS2300038I1 (hu) Stabilizált alfa-galaktozidáz és ennek alkalmazásai
IL226904A (en) Inganol-3-acetylates iii and Inganol-3-carbamates
IL249669A0 (en) Converted 5-fluoro-1h-pyrazolopyridines and their use
PL2539326T3 (pl) Połączone bis-arylem arylotriazolony i ich zastosowanie
GB201012175D0 (en) Procedure and mechanisms
EP2552953A4 (en) FRIZZLED-BINDING SUBSTANCES AND ITS USES
IL230511A0 (en) 4-Imidazopyridazine-1-yl-benzamides and 4-imidazotriazine-1-yl-benzamides as btk inhibitors
IL220939A0 (en) Compounds and methods
EP2523664A4 (en) COMPOUNDS AND METHODS
ZA201208173B (en) Peptices and their use
IL229844B (en) Anti-psgl-1 antibodies and their use
IL220812A0 (en) Compounds and methods
PL2531518T3 (pl) Związki oligopeptydowe i ich zastosowania
PL2605757T3 (pl) Preparaty oparte na nalbufinie i ich zastosowania
EP2523560A4 (en) CONNECTIONS AND METHODS
PL2547464T3 (pl) Układ i układ wentylacyjny
GB201001369D0 (en) Tri-flights and stems
GB2485537B (en) Integral -surface and air- personal transport
GB201001384D0 (en) Light-fitting and associated methods
GB201119443D0 (en) GoWinging Concept and patent
GB201014319D0 (en) Compounds and uses thereof